You are here

  • Home
  • Archive
  • Volume 11, Issue 6
  • First-line treatment of unresectable or metastatic HER2 positive esophagogastric adenocarcinoma: liquid biomarker analysis of the phase 2 INTEGA trial

Article info

Article menu
Clinical/translational cancer immunotherapy
Original research
First-line treatment of unresectable or metastatic HER2 positive esophagogastric adenocarcinoma: liquid biomarker analysis of the phase 2 INTEGA trial

Authors

  • Lisa Paschold Internal Medicine IV, Martin-Luther-University Halle-Wittenberg, Halle, Germany PubMed articlesGoogle scholar articles
  • Alexander Stein Hematology-Oncology Practice Eppendorf (HOPE), Hamburg, GermanyUniversity Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany PubMed articlesGoogle scholar articles
  • Benjamin Thiele Department of Internal Medicine II and Clinic of Oncology and Hematology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany PubMed articlesGoogle scholar articles
  • Joseph Tintelnot University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany PubMed articlesGoogle scholar articles
  • Svenja-Sibylla Henkes Internal Medicine IV, Martin-Luther-University Halle-Wittenberg, Halle, Germany PubMed articlesGoogle scholar articles
  • Cornelia Coith Institute of Tumor Biology, Center of Experimental Medicine, University Medical Center Hamburg Eppendorf, Hamburg, Germany PubMed articlesGoogle scholar articles
  • Christoph Schultheiß Internal Medicine IV, Martin-Luther-University Halle-Wittenberg, Halle, GermanyDivision of Medical Oncology, University Hospital Basel, Basel, SwitzerlandDepartment of Biomedicine, Laboratory of Translational Immuno-Oncology, University of Basel and University Hospital Basel, Basel, Switzerland PubMed articlesGoogle scholar articles
  • Klaus Pantel Institute of Tumor Biology, Center of Experimental Medicine, University Medical Center Hamburg Eppendorf, Hamburg, Germany PubMed articlesGoogle scholar articles
  • Sabine Riethdorf Institute of Tumor Biology, Center of Experimental Medicine, University Medical Center Hamburg Eppendorf, Hamburg, Germany PubMed articlesGoogle scholar articles
  • Mascha Binder Division of Medical Oncology, University Hospital Basel, Basel, SwitzerlandDepartment of Biomedicine, Laboratory of Translational Immuno-Oncology, University of Basel and University Hospital Basel, Basel, Switzerland PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Mascha Binder; mascha.binder{at}unibas.ch
View Full Text

Citation

Paschold L, Stein A, Thiele B, et al
First-line treatment of unresectable or metastatic HER2 positive esophagogastric adenocarcinoma: liquid biomarker analysis of the phase 2 INTEGA trial
Journal for ImmunoTherapy of Cancer 2023;11:e006678. doi: 10.1136/jitc-2023-006678

Publication history

  • Accepted May 30, 2023
  • First published June 16, 2023.
Online issue publication 
June 16, 2023

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.